242 related articles for article (PubMed ID: 28923647)
1. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Kim JH; Goulston C; Sanders S; Lampas M; Zangari M; Tricot G; Hanson KE
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1753-8. PubMed ID: 22728249
[TBL] [Abstract][Full Text] [Related]
5. Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients.
Annibali O; Piccioni L; Tomarchio V; Circhetta E; Sarlo C; Franceschini L; Cantonetti M; Rizzo E; Angeletti S; Tirindelli MC; Scagnolari C; Statzu M; Avvisati G; Riva E
PLoS One; 2018; 13(7):e0200221. PubMed ID: 30036376
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus reactivation following hematopoietic stem cell transplantation.
Sharma SK; Kumar S; Agrawal N; Singh L; Mukherjee A; Seth T; Mishra P; Mathur S; Dar L; Mahapatra M
J Infect Dev Ctries; 2013 Dec; 7(12):1003-7. PubMed ID: 24334950
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma.
Fassas AB; Bolaños-Meade J; Buddharaju LN; Rapoport A; Cottler-Fox M; Chen T; Lovchik JC; Cross A; Tricot G
Br J Haematol; 2001 Jan; 112(1):237-41. PubMed ID: 11167810
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
[TBL] [Abstract][Full Text] [Related]
10. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
12. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.
Hussein AA; Al-Antary ET; Najjar R; Al-Hamdan DS; Al-Zaben A; Frangoul H
Pediatr Blood Cancer; 2015 Jun; 62(6):1099-101. PubMed ID: 25346146
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y
Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.
Reed DR; Petroni GR; West M; Jones C; Alfaraj A; Williams PG; DeGregory K; Grose K; Monson S; Varadarajan I; Volodin L; Donowitz GR; Kindwall-Keller TL; Ballen KK
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):61-69. PubMed ID: 36634280
[TBL] [Abstract][Full Text] [Related]
18. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
[TBL] [Abstract][Full Text] [Related]
20. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
Serio B; Rosamilio R; Giudice V; Pepe S; Zeppa P; Esposiito S; Pezzullo L; Rocco M; Montuori N; Selleri C
Infez Med; 2012; 20 Suppl 2():26-34. PubMed ID: 23042003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]